A Proof of Concept Study of Imetelstat in Patients with Additional Hematologic Myeloid Malignancies
Latest Information Update: 26 May 2020
At a glance
- Drugs Imetelstat (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Geron Corporation
- 21 May 2020 According to an Geron Corporation media release, this study originally expected to begin in the fourth quarter of 2020, has been postponed in order to prioritize the Phase 3 clinical trials in lower risk MDS and refractory MF.
- 02 Apr 2020 According to a Geron Corporation media release, due to covid-19 pandemic we no longer expect to commence our proof of concept study in high risk MDS and AML by the end of 2020, as we had originally planned.
- 19 Mar 2020 New trial record